JPMorgan Downgrades Atea Pharmaceuticals (AVIR) to Underweight, 'Limited COVID Market With Cases and Hospitalizations Shrinking'
Tweet Send to a Friend
(Updated - August 10, 2023 4:48 AM EDT)
JPMorgan analyst Eric Joseph downgraded Atea Pharmaceuticals (NASDAQ: AVIR) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Eric Joseph downgraded Atea Pharmaceuticals (NASDAQ: AVIR) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
